title: Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats.
abstract: Fentanyl is a potent mu-opioid receptor agonist that is widely used for the treatment of chronic pain. The aim of the present study was to investigate the effect of the dose of fentanyl and the exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Fentanyl and saline were chronically administered via osmotic minipumps. A discrete-trial intracranial self-stimulation procedure was used to provide a measure of brain reward function and somatic signs were recorded from a checklist of opioid abstinence signs. The opioid receptor antagonist naloxone elevated the brain reward thresholds of the rats chronically treated with high doses of fentanyl (0.3 and 0.6mg/kg/day), but not those of rats treated with low doses of fentanyl (0.006 and 0.06mg/kg/day). Fentanyl had a dose-dependent effect on the naloxone-induced elevations in brain reward thresholds. On a similar note, the discontinuation of the administration of high doses of fentanyl was associated with elevations in brain reward thresholds and the discontinuation of the administration of low doses of fentanyl did not lead to an elevation in brain reward thresholds. The results also demonstrated that the duration of fentanyl administration does not affect naloxone-induced elevation in brain reward thresholds. In contrast, the somatic withdrawal syndrome gradually developed over time; maximum somatic signs were observed 120h after pump implantation. These studies suggest that the magnitude and duration of the negative affective signs of fentanyl withdrawal depend on the dose of fentanyl administered and not on the duration of fentanyl administration.
authors.affiliation: Department of Pharmaceutics, University of Florida, Gainesville, FL 32610, USA.
authors.forename: Jiang
authors.initials: J
authors.lastname: Liu
authors.forename: Hao
authors.initials: H
authors.lastname: Pan
authors.forename: Mark S
authors.initials: MS
authors.lastname: Gold
authors.forename: Hartmut
authors.initials: H
authors.lastname: Derendorf
authors.forename: Adrie W
authors.initials: AW
authors.lastname: Bruijnzeel
mesh_terms: D000342:Affective Symptoms / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood; D008297:Male; D009270:Naloxone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009294:Narcotics / Q000008:administration & dosage* / Q000009:adverse effects*; D051381:Rats; D017208:Rats, Wistar; D012201:Reward; D012646:Self Administration; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
chemical_list: D009292:Narcotic Antagonists; D009294:Narcotics; D009270:Naloxone; D005283:Fentanyl